ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $4.95 billion. The enterprise value is $5.57 billion.
| Market Cap | 4.95B |
| Enterprise Value | 5.57B |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 673.95 million shares outstanding. The number of shares has increased by 27.19% in one year.
| Shares Outstanding | 673.95M |
| Shares Change (YoY) | +27.19% |
| Shares Change (QoQ) | +2.06% |
| Owned by Insiders (%) | 79.62% |
| Owned by Institutions (%) | 8.79% |
| Float | 145.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7,963.90 |
| Forward PS | 501.73 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8,953.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.05
| Current Ratio | 5.05 |
| Quick Ratio | 4.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -148.40% |
| Return on Capital (ROIC) | -122.73% |
| Revenue Per Employee | $990 |
| Profits Per Employee | -$928,656 |
| Employee Count | 628 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -40,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +225.22% in the last 52 weeks. The beta is 0.04, so ImmunityBio's price volatility has been lower than the market average.
| Beta (1Y) | 0.04 |
| 52-Week Price Change | +225.22% |
| 50-Day Moving Average | 5.24 |
| 200-Day Moving Average | 3.46 |
| Relative Strength Index (RSI) | 66.00 |
| Average Volume (30 Days) | 4,847,525 |
Short Selling Information
The latest short interest is 54.84 million, so 8.14% of the outstanding shares have been sold short.
| Short Interest | 54.84M |
| Short Previous Month | 54.77M |
| Short % of Shares Out | 8.14% |
| Short % of Float | 37.75% |
| Short Ratio (days to cover) | 12.10 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $622,000 and -$583.20 million in losses. Loss per share was -$1.15.
| Revenue | 622,000 |
| Gross Profit | 622,000 |
| Operating Income | -362.25M |
| Pretax Income | -583.24M |
| Net Income | -583.20M |
| EBITDA | -429.41M |
| EBIT | -454.04M |
| Loss Per Share | -$1.15 |
Balance Sheet
The company has $266.46 million in cash and $882.14 million in debt, giving a net cash position of -$615.68 million or -$0.91 per share.
| Cash & Cash Equivalents | 266.46M |
| Total Debt | 882.14M |
| Net Cash | -615.68M |
| Net Cash Per Share | -$0.91 |
| Equity / Book Value | -586.99M |
| Book Value Per Share | -0.87 |
| Working Capital | 235.80M |
Cash Flow
In the last 12 months, operating cash flow was -$366.76 million and capital expenditures -$30.58 million, giving a free cash flow of -$397.34 million.
| Operating Cash Flow | -366.76M |
| Capital Expenditures | -30.58M |
| Free Cash Flow | -397.34M |
| FCF Per Share | -$0.78 |
Margins
Gross margin is 100.00%, with operating and profit margins of -58,239.55% and -93,761.41%.
| Gross Margin | 100.00% |
| Operating Margin | -58,239.55% |
| Pretax Margin | -93,767.85% |
| Profit Margin | -93,761.41% |
| EBITDA Margin | -69,037.62% |
| EBIT Margin | -72,996.46% |
| FCF Margin | -63,881.19% |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.19% |
| Shareholder Yield | -27.19% |
| Earnings Yield | -11.77% |
| FCF Yield | -8.02% |
Analyst Forecast
The average price target for ImmunityBio is $5.00, which is -31.97% lower than the current price. The consensus rating is "Hold".
| Price Target | $5.00 |
| Price Target Difference | -31.97% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -7.9 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.9 |
| Piotroski F-Score | 3 |